Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Massachusetts General Hospital
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Lecia V. Sequist, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01746251
First received: November 27, 2012
Last updated: September 23, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)